Editorially reviewed · Last updated July 24, 2026 · How we review
Key findings
- The 'Wolverine stack' is the peptide community's nickname for combining BPC-157 and TB-500 for injury and soft-tissue recovery — a reference to comic-book healing.
- On July 23, 2026, the FDA's advisory committee recommended both peptides for the 503A compounding list on the same day (BPC-157 8-6, TB-500 8-6-1) — which is why the name trended.
- A committee recommendation is not approval or legal access. Both still require FDA rulemaking (estimated 12-24 months), and the committee voted on each peptide individually — never on the combination.
- There is no human clinical trial on the BPC-157 + TB-500 combination, and no completed human efficacy trial on either peptide for the recovery use case.
- A pre-mixed 'blend' vial is the riskiest form, not the most convenient — you inherit both peptides' contamination, mislabeling, and reconstitution risks in one unregulated product.
- TB-500 is banned in sport under WADA, and both peptides are sold today only as unapproved 'research chemicals.'
The Wolverine Stack: BPC-157 + TB-500 Explained
Neither BPC-157 nor TB-500 is an FDA-approved drug, and the combination is not legal to prescribe or compound in the United States today. This page explains what the "Wolverine stack" is and the state of the evidence for educational purposes only. It is not medical advice, a recommendation, or encouragement to obtain, supply, or use any substance. Consult a qualified healthcare provider for any medical decision.
The "Wolverine stack" is the peptide community's nickname for running BPC-157 and TB-500 together — a reference to the comic-book character's rapid healing. The name trended in July 2026 for a concrete reason: on July 23, the FDA's advisory committee recommended both peptides for compounding on the same day, each by an 8–6 vote. As one widely shared post put it, "both halves of the Wolverine Stack made it through the panel."
This page explains what the stack actually is, what the votes do and don't mean, and the honest bottom line most sellers skip: there is no human data on the combination at all.
What Is the Wolverine Stack?
It's two separate synthetic peptides used at the same time, usually for injury or soft-tissue recovery:
| Peptide | What it is | Marketed for | Human RCT evidence |
|---|---|---|---|
| BPC-157 | 15-amino-acid 'body protective compound' | Gut and tissue healing | None published |
| TB-500 | 17-amino-acid fragment of thymosin beta-4 | Systemic soft-tissue recovery | None (a negative in-vitro result was cited by the FDA) |
The theory behind combining them is that they work through different mechanisms — BPC-157 on local tissue repair and blood-vessel growth, TB-500 on cell migration and flexibility — so together they might cover more of the healing process. That is a hypothesis, not a finding. For the details on each, see the BPC-157 explainer and the TB-500 explainer.
What the FDA Votes Mean for the Stack
Both peptides cleared the Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026:
| Peptide | PCAC vote | Legal to compound today? |
|---|---|---|
| BPC-157 | 8–6, recommended | No |
| TB-500 | 8–6–1, recommended | No |
Here's the catch that the "both halves passed" excitement glosses over: a committee recommendation is not approval, and it is not legal access. The FDA overruled its own staff (who recommended "no" on both) to hold these votes, and the agency must still complete notice-and-comment rulemaking — estimated at 12–24 months, into 2027 or beyond — before any pharmacy could legally compound either one. And the votes were per-peptide, individually. Nobody voted on the stack. A pre-mixed "BPC/TB blend" is not a substance the FDA reviewed at all.
For the full regulatory backstory, see Are Peptides Legal in 2026?.
The Evidence on the Combination
This is the single most important section, so it's blunt:
| Question | Answer |
|---|---|
| Human RCT on the BPC-157 + TB-500 combination? | None. Zero. |
| Human RCT on either peptide alone? | None completed for the recovery use case |
| Animal data on the exact combination? | Minimal; the peptides are studied separately |
| Is the combination safer because the doses are 'lower'? | No — you are adding two sets of unknowns, not averaging them |
| Does one offset the other's side effects? | No evidence for this claim |
Every confident "Wolverine stack protocol" online is built on animal studies of the individual peptides plus personal anecdote. Combining two substances that each lack human efficacy trials does not produce a proven therapy — it produces a bigger experiment with your own body as the subject.
Circulating "Blend" Doses (No Clinical Validation)
Search interest in "BPC-157 TB-500 blend dosage" and "blend calculator" is high, so to be direct: there is no validated dose for either peptide, let alone the blend. The numbers below are what circulate in the community, shown only to describe the phenomenon — not as guidance.
| Reported community practice | Typical figure cited | Reality check |
|---|---|---|
| BPC-157 portion | ~250–500 mcg, once or twice daily | No trial basis |
| TB-500 portion | ~2–2.5 mg, twice weekly (loading), then less | No trial basis |
| 'Blend' format | Pre-mixed BPC/TB vials or a shared syringe | Two unapproved substances, one unknown product — highest risk |
| Cycle | ~4–6 weeks | Not studied |
A pre-mixed blend is the riskiest form, not the most convenient: you inherit both peptides' quality problems in one vial, you can't verify either concentration, and the reconstitution math is entirely the buyer's. This is a description of risk, not a protocol to follow.
Grey-Market Safety Risks
The stack is only available today as unapproved research chemicals, so it carries every risk of grey-market peptides — doubled:
- Two products, two chances of contamination or mislabeling. Third-party testing routinely finds wrong contents and quantities.
- Immunogenicity. The FDA specifically flagged that injected peptides like TB-500 can trigger immune reactions from aggregation and impurities.
- Compounded dosing error. Reconstituting two freeze-dried peptides doubles the chance of a decimal-place mistake.
- Sport bans. TB-500 (and thymosin beta-4) is prohibited at all times under WADA; athletes have been sanctioned.
- "Not for human use." That label is a warning, not a formality.
See grey-market peptides and gray-market retatrutide for the standing guidance.
How This Relates to GLP-1 Drugs
The Wolverine stack is about recovery, not weight loss — neither peptide acts on the GLP-1, GIP, or glucagon receptors that retatrutide and other GLP-1 drugs target. The overlap is that both live on the same 503A compounding pathway, and BPC-157 and TB-500 are commonly stacked alongside GLP-1s to manage joint and soft-tissue complaints during rapid weight loss. Unlike these peptides, retatrutide's evidence comes from large published trials — a different standard of proof entirely.
Frequently Asked Questions
Is the Wolverine stack legal now?
No. Neither BPC-157 nor TB-500 is FDA-approved, and neither is legal to compound or prescribe. On July 23, 2026, an FDA advisory committee recommended both for the 503A compounding list (8–6 each), but that recommendation is advisory only — the FDA must still finalize a rule, a process estimated at 12–24 months. The committee also never voted on the combination itself.
What is in a BPC-157 / TB-500 blend?
A "blend" is simply the two separate peptides — BPC-157 (a 15-amino-acid peptide) and TB-500 (a 17-amino-acid fragment of thymosin beta-4) — used together, sometimes sold pre-mixed in one vial. There is no standardized formulation; grey-market "blends" vary by seller and are not quality-controlled.
Is a pre-mixed BPC-157/TB-500 blend safe?
A pre-mixed vial is the riskiest form, not the safest. You inherit both peptides' contamination and mislabeling risks in a single product, you cannot verify either concentration, and neither peptide is FDA-approved. There is no human data on the combination.
What is the dose for the Wolverine stack?
There is no validated dose for either peptide, so there is no validated dose for the stack. Community figures (BPC-157 around 250–500 mcg once or twice daily; TB-500 around 2–2.5 mg twice weekly) come from animal extrapolation and convention, not clinical trials — and grey-market vials are frequently mis-concentrated, so the numbers can't be relied on anyway.
Does the Wolverine stack actually work?
There is no completed human trial showing that BPC-157, TB-500, or the two combined heal injuries in people. The evidence is animal studies of the individual peptides plus personal anecdote. The FDA even cited an in-vitro study in which TB-500 failed to induce wound healing. Claims of proven results outrun the data.
Why is it called the Wolverine stack?
It's a reference to the comic-book character's rapid healing factor — the combination is marketed as accelerating tissue repair. The nickname trended in July 2026 when both peptides passed the same FDA advisory committee vote on the same day. The name is community slang, not a medical or regulatory term.
Sources
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov meeting page
- World Anti-Doping Agency. 2026 Prohibited List. WADA
- Related on this site: BPC-157 · TB-500 · Are Peptides Legal in 2026? · Grey-Market Peptides
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
BPC-157: FDA 503A Vote, Legality & Safety
The FDA panel backed BPC-157 for compounding 8-6 — but eligible isn't legal. The vote, the 2027 timeline, the evidence gap, and why Hims stock jumped.
TB-500: FDA 503A Vote, Legality & Evidence
TB-500 cleared the FDA panel 8-6-1 — but eligible isn't legal, and the evidence is thinner than the hype. The vote, the timeline, and what's actually known.
Are Peptides Legal in 2026? The FDA Reclassification Explained
RFK announced 14 banned peptides returning to legal compounding — but the FDA's July 23-24 vote only covers 7. Which ones, what it means, and how it affects weight loss drugs.
Grey Market Retatrutide: Risks, Dangers, and What You Should Know
Grey market retatrutide is unregulated, untested, and potentially dangerous. Here's what the data shows and how to access it safely.
Retatrutide Cost & How to Get It
What retatrutide might cost, how to access it through clinical trials, and why gray market peptides are dangerous.